A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

NCT03987919 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1879

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Tirzepatide
DRUG: Semaglutide

Sponsor

Eli Lilly and Company